Name Address/P.O. Box Postal Code/City Country Contact Person Telephone Fax Email Website Social Media Number of Employees Founded (year) Type of Laboratory Areas of Activity
ITM Isotope Technologies Munich SE
Targeted cancer diagnostics and therapies
›
Lichtenbergstrasse 1 85748 Garching / Munich Germany Julia Hofmann / Susanne Karlsson Corporate Communications +49-89-329-8986-6000 +49-89-329-8986-6061 communications@itm-radiopharma.com www.itm-radiopharma.com
›
LI
ITM, a radiopharmaceutical biotech company, is de dicated to providing the most precise cancer radio therapeutics and diagnostics to meet the needs of patients, clinicians and partners through excellence in development, production and global supply. With patient benefit as the driving principle, ITM is advancing a broad pipeline combining its medical radioisotopes with targeting molecules to develop precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radiopharma expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better.
›
› › › ›
› › ›
› › ›
›
370 2004 Radiopharmaceutical biotech company | Oncology | Precision Medicine | Targeted Radionuclide Therapy | Nuclear Medicine
Targeted Radionuclide Therapy or Peptide Receptor Radionuclide Therapy (PRRT) is an emerging class of cancer therapeutics, in which radiation is delivered directly to the tumor while minimizing radiation exposure to normal tissue. In contrast to conventional external radiotherapy, Targeted Radionuclide Therapy is defined by the intravenous infusion of a radiopharmaceutical. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope to a targeting molecule (e.g., peptide, antibody, small molecule) that can precisely recognize tumor cells and bind to tumor-specific characteristics. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation, thereby destroying tumor tissue. The highly precise localization enables targeted treatment with minimal impact to healthy surrounding tissue. Often, the targeting molecule can be used in a “theranostic” approach for both therapeutics and diagnostics. For diagnosis, the targeting molecule is linked with a diagnostic radioisotope, for therapy with a therapeutic radioisotope. This allows tumors and metastases to be both precisely localized at an early stage, and subsequently treated following the same mechanism.
